Raleigh, NC-based BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on the development and commercialization of treatments in the areas of pain management and drug addiction.
The company utilizes its novel, patented and proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology for the development of products. The company’s portfolio currently consists of three FDA-approved products – Onsolis (breakthrough cancer pain in opioid-tolerant adult patients), Bunavail (opioid dependence) and Belbuca (management of pain severe enough to require daily, round-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate).
Belbuca was launched by its partner Endo International plc in Feb 2016. Meanwhile, BioDelivery is currently working on driving Bunavail sales.
In this scenario, investor focus remains on the sales ramp up of Bunavail and Belbuca and other pipeline related updates apart from the usual top-and bottom-line numbers.
BioDelivery’s performance so far has been disappointing with the company beating expectations in none of the last four quarters with an average miss of 19.76%.
Currently, BioDelivery has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: BioDelivery’s fourth-quarter 2016 loss of 29 cents per share is slightly wider than consensus estimates of 28 cents per share.
Revenues: Revenues were in line with expectations in the fourth-quarter of 2017. The company posted revenues of $4 million, in the reported quarter.
Key Stats: Bunavail prescription sales increased by 4% from the prior quarter. The drug, however, saw a 64% increase in sales in 2016. The company has strategically consolidated its sales force, which will result in total savings of approximately $20 million through the end of 2017.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on this BDSI earnings report later!
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Image: Bigstock
BioDelivery Q4 Loss Wider Than Expected; Revenues in Line
Raleigh, NC-based BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on the development and commercialization of treatments in the areas of pain management and drug addiction.
The company utilizes its novel, patented and proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology for the development of products. The company’s portfolio currently consists of three FDA-approved products – Onsolis (breakthrough cancer pain in opioid-tolerant adult patients), Bunavail (opioid dependence) and Belbuca (management of pain severe enough to require daily, round-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate).
Belbuca was launched by its partner Endo International plc in Feb 2016. Meanwhile, BioDelivery is currently working on driving Bunavail sales.
In this scenario, investor focus remains on the sales ramp up of Bunavail and Belbuca and other pipeline related updates apart from the usual top-and bottom-line numbers.
BioDelivery’s performance so far has been disappointing with the company beating expectations in none of the last four quarters with an average miss of 19.76%.
BioDelivery Sciences International, Inc. Price and EPS Surprise
BioDelivery Sciences International, Inc. Price and EPS Surprise | BioDelivery Sciences International, Inc. Quote
Currently, BioDelivery has a Zacks Rank #4 (Sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: BioDelivery’s fourth-quarter 2016 loss of 29 cents per share is slightly wider than consensus estimates of 28 cents per share.
Revenues: Revenues were in line with expectations in the fourth-quarter of 2017. The company posted revenues of $4 million, in the reported quarter.
Key Stats: Bunavail prescription sales increased by 4% from the prior quarter. The drug, however, saw a 64% increase in sales in 2016. The company has strategically consolidated its sales force, which will result in total savings of approximately $20 million through the end of 2017.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on this BDSI earnings report later!
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>